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Acute retroviral syndrome developed in an inmate in a
detention center after he had intercourse with 2 HIV-
infected inmates. Correctional facilities house a dispropor-
tionate number of HIV-infected persons, and most do not
provide inmates with condoms. Correctional healthcare
providers should be familiar with primary HIV infection and
acute retroviral syndrome.
C
orrectional facilities house a disproportionate number
of HIV-infected inmates (1) and are a setting for
unprotected sexual intercourse (2). Although symptoms of
acute retroviral syndrome develop in up to 89% of persons
newly infected with HIV (3), the timely recognition and
diagnosis of primary HIV infection and initiation of anti-
retroviral treatment before HIV seroconversion have rarely
been reported from a correctional facility. 
The Case
In October 2003, a man with a history of noninjection
multiple-drug abuse (including methamphetamine) was
admitted to a detention center (regional jail). His pre-incar-
ceration history included unprotected sex with men in the
community, most recently in April 2003; however, results
of multiple serologic assays for HIV performed in the
community had been negative, most recently in June 2003
and December 2002. He had an unremarkable past medical
history.
On December 31, 2003, this patient came to the correc-
tional facility’s medical clinic with perianal and rectal dis-
comfort; perianal condylomata were present. He reported
that during December he had consensual, unprotected,
receptive anal intercourse with 2 male inmates at the cor-
rectional facility; both of these inmates had chronic HIV
infection. One, who was not receiving antiretroviral treat-
ment, had a plasma HIV RNA level of 53,000 copies/mL;
the second, who was receiving antiretroviral treatment,
had a plasma HIV RNAlevel of 92 copies/mL. On January
6, enzyme immunoassay (EIA) testing of the index patient
for HIV was negative.
On January 9, the patient came to the medical clinic
with fever, sore throat, myalgia, headache, vertigo, nausea,
and vomiting. His oral temperature was 40.7°C, and he
was profusely diaphoretic. Posterior pharyngeal erythema
was present, as well as tender, minimally enlarged, anteri-
or cervical lymphadenopathy. Laboratory testing showed
plasma HIVRNAof 436,000 copies/mL; CD4+ T-lympho-
cyte count of 616 cells/µL (28%); serum alkaline phos-
phatase 183 IU/L; and negative serologic test results for
hepatitis A, B, and C viruses. He denied participating in
tattooing or injection drug use.
On January 13, he reported vertigo and urinary reten-
tion; his temperature was 39.4°C, and he was ataxic. Acute
urinary retention required urethral catheterization. On
January 14, physical examination showed bilateral hori-
zontal nystagmus and perianal ulcerations; plasma HIV
RNA was >750,000 copies/mL. On January 15, a second
EIAfor HIV was negative; however, a Western blot of that
serum sample showed an equivocal p24 band.
On January 16, he reported difficulty defecating and
urinating. Physical examination showed a scattered macu-
lar exanthem of discrete erythematous macules on the
trunk and extremities with involvement of the palms; oral
mucositis; a tender prostate; and a friable, mildly inflamed
anal mucosa with some ulcerations and excoriations. His
persistent urinary retention required short-term urethral
catheterization. Swab cultures of the rectum for her-
pesvirus,  Chlamydia, and Neisseria gonorrhoeae were
negative. Serologic testing for syphilis was negative.
On January 20, a CD4+ T-lymphocyte count drawn on
January 15 showed 338 cells/µL (26%); plasma HIV RNA
level was 234,000 copies/mL. His exanthem had become
maculopapular, diffuse, and pruritic. Antiretroviral therapy
with efavirenz, zidovudine, and lamivudine was initiated
at the correctional facility to treat his primary HIV infec-
tion. A genotype of his pretreatment HIV isolate collected
on January 14 showed sensitivity to all antiretroviral
agents.
On January 21, he complained of paresthesias involv-
ing the tips of his fingers. On January 22, he was able to
urinate spontaneously. On January 30, he reported a poor
appetite; his weight had decreased 1.4 kg since January 16;
physical examination showed a resolving, salmon-colored
macular exanthem across the trunk and upper and lower
extremities and resolution of his oral and anal lesions.
On February 4, his plasma HIV RNA was 2,463
copies/mL, and his CD4+ T-lymphocyte count was 1,575
cells/µL. An EIAfor HIV was positive, and a Western blot
was positive with bands present for p24, gp40, p55, and
gpl60. On February 9, he reported that his appetite had
recovered and his paresthesias had resolved; his weight
had increased 0.5 kg since January 30. On March 19, his
plasma HIV RNA was <50 copies/mL, and his CD4+
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court ordered that he be released, and he moved to another
state.
Conclusions
In April 2005, Lambert et al. (4) reported concerns that
a resurgence of HIV/AIDS may be imminent, fueled in
part by increasing indicators of high-risk behavior in the
gay and bisexual population. The March 2005 report by
Markowitz et al. (5) regarding men who have sex with
men, use of methamphetamine, and transmission of HIV
underscores these concerns. The high prevalence of HIV
infection in overcrowded and understaffed correctional
facilities further accentuates these concerns and poses a
public health challenge.
On December 31, 2002, 2.0% of state prison inmates
were positive for HIV (1); among interviewed jail inmates,
1.3% disclosed they were HIV positive. Estimates of the
proportion of inmates who indulge in homosexual inter-
course while in prison range from 2% to 65%, and most of
this sexual contact is likely unsafe because few correction-
al facilities address the issue of intraprison sex or distrib-
ute condoms (2). Nevertheless, inmate-to-inmate
transmission of HIV has rarely been documented. Taylor et
al. (6) proposed that the paucity of evidence for transmis-
sion of HIV infection within correctional facilities is prob-
ably accounted for by the difficulties in determining the
time of HIV seroconversion in relation to the period of
incarceration, rather than by the rarity of the event.
Krebs and Simmons (2) used surveillance data from a
22-year period (January 1, 1978–January 1, 2000) to iden-
tify inmates who contracted HIV while incarcerated in the
Florida state prison system. They reported that a minimum
of 33 inmates contracted HIV while in prison, compared to
238 who contracted HIV after leaving prison; inmates
were more likely to have contracted HIV in prison by hav-
ing sex with other men than through injection drug use.
Additional reports of HIV transmission in correctional
facilities have been published from Illinois (8 HIV sero-
conversions) (7), Nevada (2 seroconversions) (8),
Maryland (2 seroconversions) (9), Australia (1 seroconver-
sion) (10), and Scotland (11). Yirrell et al. (11) determined
that 13 inmates had acquired HIVinfection by sharing nee-
dles during their incarceration. 
Acute retroviral syndrome and primary HIV infection
may be frequently unsuspected by the evaluating clinician
because the signs and symptoms are relatively nonspecif-
ic. However, within correctional facilities, the diagnosis of
primary HIV infection should be considered in the differ-
ential diagnosis of any inmate with an acute febrile illness
associated with pharyngitis and mucocutaneous lesions.
Our report is limited in that virus was not sequenced to
document transmission between inmates.
Early diagnosis of primary HIV infection can lead to
successful antiretroviral intervention (12) and prevention
of secondary transmission. Whether antiretroviral treat-
ment of acute HIV infection results in long-term virologic,
immunologic, or clinical benefit is unknown. In October
2005, the US Department of Health and Human Services
Clinical Practices Panel noted that antiretroviral treatment
of acute HIV infection is optional. If the clinician and
patient elect to treat acute HIV infection with antiretrovi-
ral therapy, treatment should be implemented with the goal
of suppressing plasma HIV RNA to below detectable lev-
els; resistance testing at baseline will likely optimize viro-
logic response (13).
We urge correctional facilities to address the issue of
unprotected sex among inmates and the associated trans-
mission of sexually transmitted diseases within institutions
(14). In 2001, Wolfe et al. (14) reported that from 1991 to
1999, >5 outbreaks of syphilis occurred in Alabama pris-
ons; multiple concurrent sex networks involving 4, 7, and
10 inmates were identified in the 1999 outbreak. Wolfe et
al. recommended that condom distribution should be used
to control sexually transmitted disease in correctional
facilities. Nevertheless, in 2006, <1% of US correctional
facilities provide inmates with condoms. Reasons for not
providing condoms include the conflict with policies for-
bidding sexual intercourse (or sodomy) and the potential
for condoms to be used as weapons or to smuggle contra-
band (15). In contrast, condoms are available to inmates in
all Canadian federal prisons and some provincial prisons;
few problems related to condom distribution have been
reported from those systems (15). Wolfe et al. proposed
that providing condoms to prisoners may yield additional
public health advantages beyond the prison walls if expo-
sure to and experience with condoms in this setting trans-
late into increased use after release.
Correctional staff and inmates should be educated
about the consequences of unprotected sex and the signs
and symptoms of acute retroviral syndrome. Because
many correctional systems contract for medical care, and
because staff turnover rates are high, annual education
should be implemented. Education for staff who screen
sick inmates is critical (14), and all inmates should have
access to HIV counseling and testing.
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